i-80 Gold Corp. Common Shares vs BIO-TECHNE Corp — how do they compare? i-80 Gold Corp. Common Shares trades at $1.48 (market cap $1.34B), while BIO-TECHNE Corp trades at $72.66 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 8.5× i-80 Gold Corp. Common Shares's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while i-80 Gold Corp. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold i-80 Gold Corp. Common Shares for 0 Days and BIO-TECHNE Corp for 64 Days on average.
| IAUX | TECH | |
|---|---|---|
Market Cap | $1.34B | $11.37B |
Volume | 3,239,725 | 2,420,565 |
Sector | Basic Materials | Health |
52-Week High | $2.08 | $72.61 |
52-Week Low | $0.89 | $43.31 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $1.32B | $11.39B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
IAUX trades at $1.54, down 2.53% today, with a neutral technical signal. The company shows significant financial challenges with a -198.82% net income margin and negative ROE of -71.66%, though revenue grew from $95M in 2025 to $130M in 2026. Recent positive developments include CEO purchasing 1 million shares and feasibility studies showing strong potential for Nevada gold projects. Analyst consensus remains unanimously bullish with 3 buy ratings.
While facing substantial profitability challenges, IAUX's development pipeline and CEO confidence suggest long-term potential. Key risks include persistent negative cash flow from operations and high debt levels. The stock presents a high-risk, high-reward opportunity dependent on successful project execution and gold price stability.
Bio-Techne (TECH) trades at $72.50, near its 52-week high of $72.70, with a slight daily decline of 0.08%. Technical indicators show a bullish trend, while valuation ratios like a P/E of 62.5 suggest premium pricing. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share is a key development. Earnings have been mixed, with a beat in Q2 2026 but a miss in Q1 2026, and net income declined to $73.40 million in 2025 from $168 million in 2024.
The stock's outlook is supported by the pending acquisition, offering a near-term upside to the $73.00 buyout price. However, high valuation and earnings volatility pose risks. Analyst sentiment is balanced with 46% buy ratings, but no sell recommendations. Investors should weigh the acquisition premium against fundamental concerns like margin compression.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
i-80 Gold Corp. is a mining company focused on developing and operating gold and precious-metals projects in Nevada, using a hub-and-spoke model centered on a processing facility to support multiple mine sites in the state.
Read more on IAUX →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →